Open Actively Recruiting

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

About

Brief Summary

This study will assess the safety and efficacy of Posoleucel for the treatment of adenovirus (AdV) infection in pediatric and adult allo-HCT recipients receiving standard of care (SoC).

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase III

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
N/A
Maximum Age
N/A

Inclusion Criteria:

  • Undergone allogeneic cell transplantation ≥21 days prior to dosing
  • Meet one of the below criteria:
    • AdV viremia DNA ≥10,000 copies/mL, OR
    • AdV viremia DNA results of ≥1,000 copies/mL, AND
      • has absolute lymphocyte count <180/mm3, OR
      • has received T cell depletion OR
      • had a cord blood transplant.

Exclusion Criteria:

  • Grade >2 acute GVHD
  • Ongoing therapy with high-dose systemic corticosteroids
  • Uncontrolled viral (other than AdV), bacterial, or fungal infection(s)
  • Pregnant or lactating female unwilling to discontinue nursing prior to randomization
  • History of severe prior reactions to blood product transfusions NOTE: Other protocol-defined inclusion/exclusion criterion may apply.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Share:
Study Stats
Protocol No.
22-001060
Category
Immune System/Transplant Related Disorders
Pediatric and Prenatal Disorders
Principal Investigator
Satiro Nakamura De Oliveira
Contact
Andres Vargas Gonzalez
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05179057
For detailed technical eligibility, visit ClinicalTrials.gov.